Efficacy of fluvoxamine as a treatment for behavioral symptoms in frontotemporal lobar degeneration patients.

Abstract

Patients with frontotemporal lobar degeneration (FTLD) present a profound personality change, social misconduct, overeating, and stereotyped behavior. We examined the hypothesis that many of the behavioral symptoms of FTLD will respond to selective serotonin reuptake inhibitors (SSRIs). Sixteen FTLD patients were treated with an SSRI (fluvoxamine maleate) in an open 12-week trial. Treatment responses for stereotyped behavior and other neurobehavioral symptoms were evaluated by the Stereotypy Rating Inventory and the Neuropsychiatric Inventory. The behavioral symptoms, especially stereotyped behaviors of FTLD, significantly improved after treatment. Randomized, placebo- and other SSRI-controlled trials may improve available treatments.

• Authors: Manabu Ikeda, Kazue Shigenobu, Ryuji Fukuhara, Kazuhiko Hokoishi, Naruhiko Maki, Akihiko Nebu, Kenjiro Komori, Hirotaka Tanabe
• Journal: Dementia and geriatric cognitive disorders (Dement Geriatr Cogn Disord) Vol. 17 Issue 3 Pg. 117-21 ( 2004) ISSN: 1420-8008 [Print] Switzerland
• PMID: 14739531 (Publication Type: Clinical Trial, Journal Article)
• Copyright: Copyright 2004 S. Karger AG, Basel

Chemical References

• Antidepressive Agents, Second-Generation
• Fluvoxamine

Topics

• Aged
• Antidepressive Agents, Second-Generation (therapeutic use)
• Behavior
• Female
• Fluvoxamine (therapeutic use)
• Frontal Lobe (pathology)
• Humans
• Male
• Middle Aged
• Nerve Degeneration (drug therapy, pathology)
• Neuropsychological Tests
• Psychiatric Status Rating Scales
• Temporal Lobe (pathology)
• Treatment Outcome